Infantile Spasm
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Colorado TherapeuticsCO - Louisville
1 program1
Cosyntropin Injectable Suspension, 1 mg/mLPhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Colorado TherapeuticsCosyntropin Injectable Suspension, 1 mg/mL
CerecinTricaprilin
Clinical Trials (2)
Total enrollment: 402 patients across 2 trials
A Novel Approach to Infantile Spasms
Start: Apr 2018Est. completion: Aug 2021394 patients
Phase 3Suspended
Tricaprilin Infantile Spasms Pilot Study
Start: Nov 2021Est. completion: Dec 20238 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.